Laverock Therapeutics

Combining #GeneEditing and RNAi can enhance #AdvancedTherapies. Read our recent article for BioInsights where Vlad Seitan, CSO, discusses GEiGS technology and its advantages in iPSC-derived allogeneic cell therapy. @CGT_Insights laverocktx.com/exploring-the-…

We’re pleased to announce £1m funding via the @InnovateUK Investor Partnerships Future Economy programme with support from @UKI2S to progress our immune effector cell therapeutic programme aiming to combat hard-to-treat cancers. laverocktx.com/laverock-thera… @UKRI_News

We’re at #ESGCT2023 this week discussing how GEiGS technology enables the development of products with improved efficacy, safety and accessibility. Interested in partnering? Meet us at one of our posters P516, P582 and P706. laverocktx.com/laverock-thera… @ESGCT

Will you be at #ESGCT2023 next week? We’ll be presenting a series of posters looking at the therapeutic applications of our #GeneEditing technology, get in touch to arrange a meeting at the conference. laverocktx.com/laverock-thera… @ESGCT

What a great first day at #CGMesa23, looking forward to many more engaging discussions over the next two days. Don’t miss our company presentation at 11am on 12th October. @alliancerm laverocktx.com/laverock-thera… #CellTherapy #GeneTherapy

Will the #ATMP sector see a return to previous levels of funding? Join the debate with experts from @CGTCatapult @ComplementTx, Bone Therapeutics @EliLillyandCo @pdc_line @ParkwalkAdvisor & Laverock at #AdvancedTherapiesIntegrates, sponsored by @SteBioCat lifescienceintegrates.com/event/advanced…

We’re looking forward to connecting with senior executives and top stakeholders to discuss the latest progress in #CellandGeneTherapies @alliancerm’s #CGMesa23! Our CEO will be presenting at 11am on 12th October - See you in California! laverocktx.com/laverock-thera…

Today @LaverockTx, established in 2021 to commercialise the gene editing induced gene silencing (GEiGS®) platform for all human therapeutic applications, is pleased to announce that it has expanded its seed funding round to £13.5M. sciad.com/news/laverock-…

We’re pleased to announce that we’ve raised £13.5M to continue development of GEiGS technology and progress our programmes in #RegenerativeMedicine and #ImmunoOncology. laverocktx.com/laverock-thera…

Fantastic week at #ASGCT23 connecting with some real drivers of #CellTherapy & #GeneTherapy development. If you missed us, please get in touch to find out more about Laverock and GEiGS. laverocktx.com/contact-us

It was great to see so many people at our #ASGCT23 poster yesterday and to share our new data on the stability, tunability and programmability attributes of GEiGS gene silencing. Stop by poster 759 if you missed it! annualmeeting.asgct.org/abstracts/abst…

Tom Payne and Vlad Seitan are at #ASGCT23 to meet with opinion leaders & scientific researchers, to talk about LaverockTx's mission: using our Gene Editing induced Gene Silencing (GEiGS) platform to engineer widely available next gen. #celltherapies, with positive health outcomes

Founded to develop next gen programmable #celltherapies, Laverock has a growing team of scientific innovators & business leaders driving exciting advances in cell & gene therapies. This week we're at #ASGCT23 to talk about our technology & partnering opportunities. See you there!

Terence R. Flotte, MD, newly elected vice president of @ASGCTherapy, describes his leadership approach at @UMassChan and discusses his work investigating the use of #genetherapy for genetic diseases in kids on the “Giants of Gene Therapy” #podcast: direc.to/jpSX @HPKiem

We can't wait to see you TOMORROW for the start of #ASGCT23! Already registered? Here's what you should know before you go: ow.ly/ieuH50On6V7 Not yet registered? Attend in person in Los Angeles or watch virtually from anywhere! #genetherapy #celltherapy

On the way to LA for #ASGCT23 and looking forward to seeing old friends & making new ones. We're delighted to be presenting our gene editing induced gene silencing (GEiGS) platform & to share a key update ahead of our session on Wednesday bit.ly/3W16i49

ASGCT met with @RepBarragan’s staff on the #CGT pipeline, with a special focus on #CART and other treatments for cancer. Thank you for your attention to these transformative therapies! #ASGCTadvocacy